Apeximmune Therapeutics
PrivateLast Round
Series A
Mar 31, 2025
Total Funding Raised
$27.7M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Apeximmune Therapeutics operates in Healthcare & Life Sciences and is based in Burlingame, California. Its latest recorded funding round was a Series A round in March 2025.
Apeximmune Therapeutics is a biotechnology company that develops novel biologics and therapeutic antibodies designed to modulate the immune system for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apeximmune Therapeutics Comparables
Compare Apeximmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pheast Therapeutics | 83% | |
| Agni Bio, Inc. | 83% | |
| Immune-Onc Therapeutics | 83% |
For institutional investors. Book with your work email.
Apeximmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 31, 2025 | ||||
| Grant | Jun 1, 2023 | ||||
| Seed | Mar 15, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Apeximmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| DCI Partners | Series A |
| TA YA VENTURE HOLDINGS LIMITED | Series A |
| Hercules Bioventure Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 5, 2026
Grew 80% QoQ, from 5 to 9 employees.
- Aug 24, 2026
Grew 60% QoQ from 5 to 8 employees.
For institutional investors. Book with your work email.
Apeximmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Apeximmune Therapeutics's valuation, stock price, and market status.
Is Apeximmune Therapeutics a public or private company?
Apeximmune Therapeutics is a private company.
What is the current stock price of Apeximmune Therapeutics?
Apeximmune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Apeximmune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Apeximmune Therapeutics worth (valuation)?
Valuation information for Apeximmune Therapeutics is not publicly available.
Can I buy Apeximmune Therapeutics stock?
Apeximmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Apeximmune Therapeutics's last funding round?
Apeximmune Therapeutics's most recent funding round was Series A on March 31, 2025.
Who are the main investors in Apeximmune Therapeutics?
Key investors in Apeximmune Therapeutics include NIH RADx, DCI Partners, TA YA VENTURE HOLDINGS LIMITED, Hercules Bioventure Partners.
Will Apeximmune Therapeutics IPO soon?
No public IPO plans have been announced for Apeximmune Therapeutics.
How can I track Apeximmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Apeximmune Therapeutics's shares on secondary markets.